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RESEARCH ARTICLE
ICAM-2 facilitates luminal interactions between neutrophils and
endothelial cells in vivo
Krishma Halai, James Whiteford, Bin Ma, Sussan Nourshargh and Abigail Woodfin*,{
ABSTRACT
Intercellular adhesion molecule 2 (ICAM-2) is expressed on
endothelial cells (ECs) and supports neutrophil extravasation.
However, the full details of its role remain unknown, and the
present study investigates the functional mechanisms of ICAM-2 in
neutrophil–endothelial-cell interactions. Our initial studies showed
expression of ICAM-2 at both EC junctions and on the EC body. In
line with the observed expression profile analysis of neutrophil–
vessel-wall interactions using real-time in vivo confocal microscopy
identified numerous functional roles for ICAM-2 within the vascular
lumen and at the stage of neutrophil extravasation. Functional or
genetic blockade of ICAM-2 significantly reduced neutrophil
crawling velocity, increased frequency of crawling with a disrupted
stop-start profile, and prolonged interaction of neutrophils with EC
junctions prior to transendothelial cell migration (TEM), collectively
resulting in significantly reduced extravasation. Pharmacological
blockade of the leukocyte integrin MAC-1 indicated that some
ICAM-2-dependent functions might be mediated through ligation of
this integrin. These findings highlight novel roles for ICAM-2 in
mediating luminal neutrophil crawling and the effect on subsequent
levels of extravasation.
KEY WORDS: Intercellular adhesion molecule 2, ICAM-2,
Leukocyte, Neutrophil, Extravasation, Intravascular crawling
INTRODUCTION
Leukocyte extravasation from blood vessels into surrounding
tissues is a crucial component of physiological and pathological
inflammation. In recent years, many studies, particularly those
employing imaging modalities, have significantly furthered our
understanding of the profile and mechanisms that support this
process. Extravasation occurs through a series of distinct stages,
with each step being tightly regulated through defined molecular
interactions between leukocytes and components of the venular
wall. Specifically, in order to enter the extravascular tissue,
migrating leukocytes must first breach endothelial cells (ECs)
that line the vessel lumen and then cross the perivascular pericyte
layer embedded within the dense matrix protein structure of the
vascular basement membrane (Nourshargh et al., 2010).
Extravasation begins with tethering and rolling of leukocytes
along the luminal endothelium followed by slow rolling that
enables the establishment of a stronger interaction between
leukocytes and ECs, responses largely triggered and mediated by
surface-expressed chemokines (Ley et al., 2007). To initiate
extravasation, firmly adherent cells polarise and crawl along the
luminal aspect of endothelial cells, seeking to identify permissive
sites in the venular wall.
The molecular interactions that mediate the above adhesion
cascade have been studied extensively and many aspects are now
well characterised. As well as better understanding of the initial
luminal responses of rolling and crawling, there is now an
abundance of information regarding the role of numerous EC
junctional proteins, such as platelet endothelial cell adhesion
molecule (PECAM-1), junctional adhesion molecule (JAM)-A,
JAM-C, CD99, endothelial cell-selective adhesion molecule
(ESAM) and intercellular adhesion molecule 2 (ICAM-2, also
known as CD102), in regulation of leukocyte transendothelial
migration (TEM) (Ley et al., 2007; Nourshargh et al., 2010).
Despite this significant progress, understanding the details of the
dynamics of luminal leukocyte–vessel-wall interactions in vivo
requires further investigation, and there is a need for more in-
depth analysis of the functions role of key adhesion molecules.
One EC adhesion molecule that has not been extensively studied
is ICAM-2.
ICAM-2 is a 55–65 kDa b2 integrin ligand member of the
immunoglobulin superfamily that is constitutively expressed on
ECs and has also been reported to be expressed on a number of
leukocyte subsets, including monocytes, eosinophils, T and B
lymphocytes and neutrophils (de Fougerolles et al., 1991; Sundd
et al., 2012). On ECs the expression of ICAM-2 is not generally
considered to be regulated during inflammation (de Fougerolles
et al., 1991), although a limited number of in vitro studies have
indicated that its expression is reduced post cytokine stimulation
in cultured ECs (McLaughlin et al., 1998). ICAM-2 ligands have
been identified as the b2 integrin-containing lymphocyte
function-associated antigen 1 (LFA-1) (Li et al., 1993; Staunton
et al., 1989) and macrophage-1 antigen (MAC-1) (Xie et al.,
1995), and DC-SIGN (Geijtenbeek et al., 2000). ICAM-2 forms
intracellular interactions with ezrin (Heiska et al., 1996;
Yonemura et al., 1998) and a-actinin (Heiska et al., 1996), and
has also been demonstrated to bind in a homophilic manner
in trans, a response implicated in EC tube formation and
angiogenesis (Huang et al., 2005).
In contrast to many EC junctional proteins, ICAM-2 has
not been extensively investigated in relation to leukocyte
extravasation; however, a number of studies have demonstrated a
role for this molecule in recruitment of lymphocytes (Boscacci
et al., 2010; Lehmann et al., 2003; Steiner et al., 2010), neutrophils
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(Huang et al., 2006; Issekutz et al., 1999), monocytes (Schenkel
et al., 2004), eosinophils (Gerwin et al., 1999) and dendritic cells
(Geijtenbeek et al., 2000), although few have sought to identify the
mechanisms underlying the observed roles for ICAM-2. Of those
that have addressed this issue, findings indicate that EC ICAM-2 is
involved in monocyte ‘locomotion’ on human umbilical vein
endothelial cells (HUVECs) through its interaction with b2
integrins (Schenkel et al., 2004), and supports lymphocyte
polarisation and crawling on a blood–brain barrier model in vitro
(Steiner et al., 2010). Few studies, however, have addressed the
functional profile of ICAM-2 and the mechanisms through which
ICAM-2 supports leukocyte extravasation in vivo. Previous work
from our laboratory has provided direct in vivo evidence for the
involvement of EC ICAM-2 in the early phases of neutrophil
extravasation (Huang et al., 2006; Woodfin et al., 2009), although
details of this process remain unknown. To extend these findings in
the present study we have used confocal intravital microscopy
(IVM) to conduct an in-depth analysis of the functional role of
ICAM-2 in the dynamics of neutrophil–vessel-wall interactions
in vivo.
We used ICAM-2-deficient mice and pharmacological blockade
of ICAM-2, and found a key role for ICAM-2 in the regulation of
neutrophil crawling dynamics, and we describe mechanisms that
are crucial in supporting neutrophil migration to EC junctions and a
possible role during the initiation of an efficient neutrophil TEM
response. The results of this study suggest that these ICAM-2-
dependent responses may be at least partly mediated through
ICAM-2–MAC-1 interactions. Collectively the present work
provides evidence for previously unreported functions of ICAM-
2 in supporting luminal neutrophil–vessel-wall interactions in vivo,
responses that can account for the role of ICAM-2 in mediating
neutrophil extravasation in acute inflammatory responses.
RESULTS
ICAM-2 is expressed at endothelial cell junctions and on the
endothelial cell body
Although ICAM-2 is commonly considered to be an endothelial
cell junctional protein, we have previously shown that in vivo it is
also expressed on the EC body (Woodfin et al., 2009). To extend
these findings a detailed quantitative analysis of the expression of
ICAM-2 in the mouse cremaster muscle microcirculation was
performed. Specifically the level and localisation of ICAM-2
expression was investigated in comparison to other key EC
junctional adhesion molecules, PECAM-1 and VE-cadherin, by
immunofluorescence staining and confocal microscopy of fixed
whole-mount cremaster muscles. ICAM-2, PECAM-1 and VE-
cadherin were all expressed in cremaster muscle arterioles,
venules and lymphatic vessels (supplementary material Fig.
S1A). The expression profile of PECAM-1 and ICAM-2 in post-
capillary venules, the primary sites of neutrophil TEM, was
analysed in more detail. Whereas PECAM-1 showed enriched EC
junctional expression, ICAM-2 was expressed to an almost equal
level in both junctional and non-junctional regions of the
endothelium (Fig. 1; supplementary material Fig. S1B). A
similar expression profile was also found in ear dermal post-
capillary venules (supplementary material Fig. S1C). High-
magnification optical sections of vessels labelled for ICAM-2,
PECAM-1 and Draq5 (a nuclear marker) showed that PECAM-1
and ICAM-2 were on the luminal side of the EC nuclei,
confirming that the non-junctional ICAM-2 is expressed on the
luminal surface of ECs (Fig. 1C). The specificity of our ICAM-2-
labelling protocol was illustrated by lack of labelling of tissues
Fig. 1. PECAM-1 and ICAM-2 expression in cremasteric post-capillary
venules. Venular expression and localisation of PECAM-1 and ICAM-2 was
investigated in saline and IL-1b-stimulated WT or ICAM-2 KO tissues by
immunofluorescence labelling and post-acquisition analysis of junctional and
non-junctional regions of endothelial cells. (A) Representative images of
venules from WT tissues which were labelled in vivo with an i.s. injection of
fluorescent anti-PECAM-1 or anti-ICAM-2 mAb. Anti-ICAM-2 mAb specificity
was confirmed by immunolabelling cremaster muscles from ICAM-2 KO
mice. The brightly labelled perivascular structures are phagocytic cells,
which non-specifically take up antibodies during the in vivo labelling protocol.
Scale bars: 20 mm. (B) Linear transect intensity profile of a two-dimensional
maximal intensity projection of a PECAM-1- and ICAM-2-labelled vessel,
showing high intensity PECAM-1 peaks at the EC junctions. (C) Draq5 was
used to label the nuclei of ICAM-2- and PECAM-1-labelled vessels, and high-
magnification optical sections were examined to determine whether PECAM-
1 and ICAM-2 were expressed on the luminal and/or abluminal side of the
nucleus, indicating expression on the luminal or abluminal EC surface.
(D) Junctional and non-junctional distribution of PECAM-1 and ICAM-2 was
quantified from 3D models of IL-1b- or saline-stimulated vessels using Imaris
software (see supplementary material Fig. S1B for the isosurface method).
n53–5 vessels per mice, three mice per group, error bars show s.e.m.
***P,0.001 between junctional or non-junctional regions; ##P,0.01,
###P,0.001 between WT and ICAM-2 KO (all Student’s t-test).
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from ICAM-2-deficient mice (Fig. 1). Of importance, the
expression profile of ICAM-2, and also that of PECAM-1, was
quantitatively similar in both saline and IL-1b-stimulated (50 ng,
4 hours) cremaster muscles (Fig. 1D). The presence of substantial
amounts of constitutively expressed ICAM-2 on the EC body, as
well as EC junctions, suggests that ICAM-2 might support
luminal leukocyte–EC interactions in addition to mediating
leukocyte TEM, a question that was investigated next.
ICAM-2 supports dynamics of neutrophil luminal crawling
To enable investigation of the functional role of ICAM-2 in the
dynamics of neutrophil–vessel interactions in vivo, ICAM-2
deficient mice were crossed with LysM-EGFP-ki mice yielding
ICAM-2 knockout (KO) mice with endogenous expression of
GFP in neutrophils and monocytes. Monocytes could be excluded
from analysis by their substantially lower levels of GFP
expression. Initial studies showed that as we have previously
found with the pure ICAM-2 KO mice (Huang et al., 2006;
Woodfin et al., 2009), the ICAM-22/2/LysM-EGFP+/2 mice
exhibit reduced IL-1b stimulated neutrophil extravasation but
normal adhesion in cremasteric venules (supplementary material
Fig. S2). To investigate dynamics of luminal neutrophil–vessel-
wall interactions, neutrophil responses were analysed using
confocal IVM as previously detailed (Woodfin et al., 2011).
Briefly, the cremasteric vasculature of wild-type (WT), ICAM-
22/2/LysM-EGFP+/2, or LysM-EGFP+/2 mice treated with an
anti-ICAM-2 blocking mAb or an isotype control [3 mg per kg of
body weight, intravenously (i.v.)], were labelled with fluorescent
anti-PECAM-1 mAb, and tissues were stimulated with IL-1b
[50 ng, intrascrotal injection (i.s.)] for 2 hours. Following
exteriorisation, selected post-capillary venules were imaged at
30-second intervals for a further 2 hours (,30–40 minutes per
vessel). Post-acquisition, the sequential image stacks were
converted into dynamic 3D models, and the migratory
behaviour of individual cells was manually tracked and
quantified using the image analysis software Imaris. Examples
of inflamed (IL-1b stimulated) and uninflamed (unstimulated)
vessels, and the tracking of an individual neutrophil are shown in
supplementary material Movies 1–3. No differences between WT
and WT with isotype control treatments were seen, so these
groups were pooled.
Using the above technique, the frequency of crawling, and non-
crawling or immobile cells within the luminally adherent
population was quantified (supplementary material Movies 3
and 4). No difference in rolling frequency was seen in ICAM-2
KO animals (data not shown), and rolling cells were excluded
from this analysis. In each group, the majority of adherent cells
exhibited crawling behaviour (defined as movement of .5 mm
during observation), with a small but significant reduction in
crawling frequency in the ICAM-2 deficient animals [96.862.5%
in WT and 80.464.7% in ICAM-2 KO (6s.e.m.)] (Fig. 2A). The
observed duration of neutrophil crawling was significantly
increased in ICAM-2 KO and antibody-treated mice
[9.260.7 minutes in WT, 13.161.1 minutes in KO and
11.560.7 minutes in the anti-ICAM-2 mAb group (6s.e.m.)]
(Fig. 2B). A significant reduction in mean crawling speed was
also detected in ICAM-2 KO and WT mice treated with anti-
ICAM-2 antibody [10.460.5 mm/minute in WT, 6.360.3 mm/
minute in KO and 6.760.3 mm/minute WT mice treated with
anti-ICAM-2 mAb (6s.e.m.)] (Fig. 2C). In order to determine
whether ICAM-2 expressed on the luminal surface of ECs
supports crawling or if EC junctional ICAM-2 plays the primary
Fig. 2. Role of ICAM-2 in IL-1b stimulated neutrophil luminal
crawling dynamics. Cremasteric post-capillary venules of WT or ICAM-
22/2/LysM-EGFP+/2 mice, or WT LysM-EGFP+/2 mice treated with anti-
ICAM-2 blocking mAb (3 mg per kg of body weight, i.v.) were analysed.
Tissues were labelled in vivo with an i.s. injection of fluorescent anti-
PECAM-1 mAb (4 mg i.s.) and co-injected with IL-1b (50 ng i.s.) 2 hours
prior to exteriorisation. Sequential confocal images of selected venules
were captured at 30-second intervals, for ,30 minutes per venule, for a
further 2 hours. (A) The behaviour of luminal neutrophils was analysed,
and the percentage of adherent neutrophils that exhibited crawling per
venule was quantified. Crawling dynamics were also quantified from
these sequences. Mean (B) duration, (C) speed, (D) speed on EC bodies
(and supplementary material Fig. S3), and (E) speed variability (standard
deviation of crawling speed per cell, divided by the mean crawling speed
per cell) of crawling cells is shown. (F) The behaviour of crawling cells
was identified as being either continuous or discontinuous, and the
percentage of these behaviours among all crawling cells was quantified
per vessel. Other crawling dynamics of continuously and discontinuously
crawling cells was compared, and the mean (G) duration and (H) speed
of continuously and discontinuously crawling cells in each mouse strain
is shown. n576–81 cells (from 10 vessels) in six or seven mice per
group, error bars show s.e.m. *P,0.05, **P,0.01, ***P,0.001 between
WT and antibody-treated or ICAM-2 KO mice; ###P,0.001 between
continuous or discontinuous crawling parameters (Student’s t-test
or ANOVA).
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functional role, neutrophil crawling tracks were analysed in detail
and time points during which crawling cells were only in contact
with EC bodies, not junctions, were identified (supplementary
material Fig. S3). This analysis showed a significant reduction in
neutrophil crawling speed on EC bodies in the ICAM-2 KO
vessels (Fig. 2D).
Of note, the variability of crawling speed of individual cells
(standard deviation of crawling speed per cell, divided by the mean
crawling speed per cell) was significantly higher in the ICAM-2 KO
and antibody-treated mice (Fig. 2E). No difference was detected in
neutrophil crawling straightness or displacement (data not shown). In
each group, the net crawling displacement direction relative to blood
flow was predominately with or perpendicular to the direction of
blood flow, with few cells crawling against the direction of flow
[87.266.5% in WT, 93.264.9% in ICAM-2 KO and 95.865.8% after
anti-ICAM-2 mAb treatment (6s.e.m.)].
These data indicate that ICAM-2 is not essential for initial
adhesion or the exhibition of crawling behaviour, but that there is
a role for ICAM-2 in supporting efficient luminal crawling with
respect to its velocity.
ICAM-2 impacts on the profile of neutrophil crawling
While analysing crawling dynamics it was noted that neutrophils
exhibited different modes of crawling. Specifically, some
neutrophils exhibited continuous crawling, in that they were
motile for the full duration of observations but others exhibited
periods of immobility with a mean duration of,7 minutes. These
behaviours have been termed ‘continuous’ and ‘discontinuous’
crawling respectively, and are illustrated in supplementary
material Movies 5 and 6. Quantification of the frequency at
which these responses occurred in IL-1b-stimulated tissues
showed that whereas in WT mice the majority [87.265.6%
(6s.e.m.)] of crawling cells had a continuous crawling profile, in
ICAM-2 KO and animals treated with anti-ICAM-2 antibody
there was a shift towards a greater frequency of discontinuous
crawling (48.568.8% in KOs and 45.167.4% after anti-ICAM-2
treatment) (Fig. 2F), with a .50% reduction in continuous
crawling. Not surprisingly, in both WT and ICAM-2 KO mice,
neutrophils that exhibited discontinuous crawling also showed a
significantly reduced average crawling speed and increased
duration of luminal crawling (Fig. 2G,H), and the same effects
were seen in the presence of anti-ICAM-2 mAb (data not shown).
However, when only continuously crawling cells were compared
between WT and ICAM-2 KO mice, the latter still showed a
reduction in speed (Fig. 2H), collectively suggesting that in the
absence of functional ICAM-2 there is a reduction in both
neutrophil crawling speed and continuity.
ICAM-2-mediated crawling might be mediated through MAC-1 ligation
The neutrophil integrin MAC-1 is a known ICAM-2 ligand, and it
was hypothesised that ICAM-2–MAC-1 interactions could mediate
the observed role of ICAM-2 in neutrophil crawling. The possibility
that any observed effect of blocking MAC-1 was related to
inhibition of MAC-1–ICAM-1 interactions was also considered, as
this integrin is also known to bind ICAM-1 (Phillipson et al., 2006;
Smith et al., 1989; Sumagin et al., 2010). As expected ICAM-1 was
upregulated in IL-1b-stimulated tissues in both WT and ICAM-2
KO mice, but no evidence was found for ICAM-2 KO specific
changes in ICAM-1 distribution or an additional compensatory
increase in ICAM-1 expression (supplementary material Fig. S4).
WT or ICAM-2 KO animals were given 3 mg per kg of body
weight (i.v.) anti-MAC-1 or anti-ICAM-1 blocking mAb, or
matched isotype control, and cremaster muscles were labelled for
PECAM-1 and stimulated with IL-1b as described above. To
confirm the effectiveness of these interventions, at the end of the
live-imaging experiments, ,4 hours post IL-1b, still images of
post-capillary venules were captured and intravascular and
extravasated neutrophil numbers were quantified (Fig. 3A,B). In
the ICAM-2-deficient animals, extravasation but not luminal
adhesion was reduced, and this was also seen when anti-ICAM-2
blocking mAb was used (not shown). By contrast, anti-ICAM-1 or
anti-MAC-1 inhibition reduced both adhesion and transmigration,
although ICAM-1 blockade has a more profound effect on
adhesion than MAC-1 inhibition (Fig. 3A,B). The differential
effect of blocking ICAM-1 or ICAM-2 on numbers of adherent
neutrophils indicates that the roles of these proteins are not fully
redundant in this model. These data, coupled with previously
published work, suggest that ICAM-1–MAC-1 binding, along with
other possible ICAM-1 ligands, such as LFA-1, supports luminal
adhesion (Phillipson et al., 2006; Sumagin et al., 2010).
The role of MAC-1 and ICAM-2 interactions in luminal
crawling was further investigated. Definitively excluding a
contribution of ICAM-1–MAC-1 binding in these studies was
not possible, as use of an ICAM-1 blocking antibody abolishes
luminal adhesion and so precludes subsequent analysis of
crawling dynamics. Owing to this limitation, the effect of an
anti-MAC-1 blocking mAb in WT and ICAM-2 KO mice was
compared on the basis that a lack of a cumulative effect of MAC-
1 inhibition in ICAM-2 KO vessels would indicate that the
observed effect represents the function of these two proteins
interacting or acting in series within the same pathway.
Analysis of crawling speed showed that treatment of WT mice
with anti-MAC-1 resulted in a reduction in crawling speed
comparable to the reduction seen in ICAM-2 KO mice (Fig. 3C).
When ICAM-2 KO mice were treated with anti-MAC-1 antibody,
no further reduction in crawling speed was seen (10.260.34 mm/
minute in WT, 7.360.3 mm/minute in WT with MAC-1 mAb,
6.360.3 mm/minute in ICAM-2 KO and 6.760.7 mm/minute in
ICAM-2 KO with anti-MAC-1 mAb). The same lack of cumulative
inhibition was seen when the percentage of continuously crawling
cells was quantified in the presence of MAC-1 blockade
(76.264.6% in WT with isotype, 50.469.1 in WT with anti-
MAC-1 mAb, 25610.2% in ICAM-2 KO with isotype control, and
33.864.1% in ICAM-2 KO with anti-MAC-1 mAb) (Fig. 3D).
In order to clarify the role of direct of ICAM-2–MAC-1
interactions in neutrophil crawling in the absence of any ICAM-1-
mediated effects, and to exclude the possibility that another MAC-1
ligand might be acting in sequence with ICAM-2, we analysed
crawling behaviour in vitro. Glass chamber slides were coated with
BSA alone, BSA and ICAM-2, or BSA and ICAM-1. The crawling
behaviour of freshly isolated and fluorescently labelled murine blood
neutrophils on these surfaces was analysed in the presence or absence
of anti-MAC-1 mAb (Fig. 4A; supplementary material Movies 7 and
8). A static system was used, as in the absence of ICAM-1-mediated
firm adhesion very few cells crawling cells were retained under flow
conditions with anti-MAC1 treatment. In these no-flow conditions,
neutrophils were able to adhere to ICAM-2 and exhibited random
crawling behaviour, albeit at a lower velocity than that seen in vivo.
When anti-MAC-1 antibody was added to the chamber, there was a
significant reduction in crawling speed and total distance crawled
(Fig. 4B,C). A similar pattern of random crawling and anti-MAC-1
mAb inhibition of crawling speed and distance was seen on ICAM-1-
coated surfaces and when CXCL1 was included in the ICAM-2
coating (not shown).
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Collectively these in vivo and in vitro data provide evidence
indicating that binding to ICAM-2 activates signalling pathways
within neutrophils, and ICAM-2–MAC-1 binding supports the
observed role of ICAM-2 in luminal neutrophil–EC interactions.
ICAM-2 might facilitate the initiation of TEM
In addition to exhibiting crawling defects, ICAM-2 KO mice
showed a significant reduction in the frequency of TEM (5.562.1
TEM events/30 minutes in KO mice and 22.1864.6 events/
30 minutes in WT) (Fig. 5A). In both groups, however, more than
90% of TEM events occurred through the paracellular route with
no differences between the two mouse strains in terms of the
route of TEM (Fig. 5B; supplementary material Movie 9).
A relatively small percentage of crawling cells analysed were
observed to undergo TEM (17.465.9% in WT and 7.965.2% in
ICAM-2 KO). This is partly owing to the technical limitations
involved in tracking an individual neutrophil from initial
adhesion to TEM within a limited time period and field of
view. However, when a cell was observed to transmigrate, the
crawling behaviour that preceded transmigration was examined.
It was found that in both genotypes 80–90% of transmigrating
neutrophils had previously crawled in a continuous rather than a
discontinuous manner (Fig. 5C). Hence, in the ICAM-2 KO mice
,50% of total crawling cells show discontinuous crawling, but
.80% of those that transmigrated previously exhibited
continuous crawling, indicating that those that do crawl
continuously are much more likely to successfully transmigrate.
In order to ascertain how ICAM-2 was supporting neutrophil
TEM, the cellular events leading to neutrophil TEM, and TEM
itself were divided into distinct quantifiable steps (Fig. 5D),
Fig. 3. MAC-1 interactions with ICAM-1 and ICAM-2 support luminal
adhesion and crawling. The contribution of ICAM-1 and ICAM-2 ligation of
leukocyte MAC-1 to IL-1b-stimulated adhesion, crawling and extravasation
was investigated. WT or ICAM-22/2/LysM-EGFP+/2 mice were pre-treated
with anti-ICAM-1 or MAC-1 blocking mAb, or isotype control (3 mg per kg of
body weight, i.v.). Tissues were labelled in vivo with an i.s. injection of
fluorescent anti-PECAM-1 mAb (4 mg i.s.), and co-injected with IL-1b (50 ng
i.s.) 2 hours prior to exteriorisation. (A) The effect of genetic and
pharmacological interventions was confirmed by capturing images at the end
of the experiment (4 hours post stimulation) Scale bars: 10 mm. (B) The
number of intravascular and extravasated neutrophils at this time point was
quantified in each condition. Images and data are representative of three to
five vessels per cremaster muscle (n53–8 mice per group). (C) Sequential
confocal images of selected venules were captured at 30-second intervals
for ,30 minutes per venule, from 2–4 hours post stimulation. Neutrophil
crawling speed was quantified in IL-1b-stimulated animals pre-treated with
blocking mAbs or isotype control. (D) The percentage of continuously or
discontinuously crawling neutrophils per venule was determined in each
group. Data were obtained from analysis of 66–113 crawling cells from four to
nine vessels in four to eight mice. Results are mean 6 s.e.m. for all
events analysed. **P,0.01, ***P,0.001 between unstimulated and IL-1b
treated groups; #P,0.05, ###P,0.001 between isotype and blocking
antibody, or WT and KO, group; $P,0.05, $$P,0.01 between blocking
antibodies (all ANOVA). n.d., not significantly different.
Fig. 4. In vitro crawling on ICAM-1 or ICAM-2. (A). Neutrophils were
fluorescently labelled with Calcein-AM and seeded into un-coated (BSA
blocked), or ICAM-2- or ICAM-1-coated chamber slides. Following adhesion,
anti-MAC-1 mAb (5 mg/ml) was added to some groups. Images were
captured at 2-minute intervals and crawling dynamics were analysed using
Imaris. Examples show the position of neutrophils at t50 in green, and the
crawling tracks over the following 40-minute period in black. Neutrophil
crawling speed (B) and total crawling distance (C) was quantified on
uncoated, ICAM-2- and ICAM-1-coated glass, with or without anti-MAC-1
mAb. Data were obtained from analysis of .300 crawling cells per group
from four or five mice. The black lines show the mean6s.e.m. for all events
analysed. ***P,0.001 between uncoated and ICAM-1/2 coated groups;
###P,0.001 between isotype and blocking antibody groups (all ANOVA).
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namely (i) crawling to the site of TEM, (ii) interaction with the
junction prior to initiation of TEM, referred to as ‘pre-TEM’
(from arrival at the junction until the first visible disruption of the
junctional PECAM-1), and (iii) TEM itself (the time from first
disruption of the junction to completion of migration of the
neutrophil through the junctional pore). In line with previous data
(Fig. 2B), the observed duration of crawling to the site of TEM
was significantly longer in ICAM-2 KO mice (3.360.4 minutes
in WT and 7.161.5 minutes in ICAM-2 KO) (Fig. 5E, stage i).
The interaction of neutrophils with their site of TEM prior to any
detectable disruption of the PECAM-1-enriched junction (pre-
TEM) was significantly prolonged in ICAM-2 KO mice in
comparison to WT mice (3.260.3 minutes in KO and
1.160.1 minutes in WT) (Fig. 5E, stage ii). Interestingly no
difference in the duration of TEM itself was noted, and in both
WT and ICAM-2 KO mice the duration of this step was
,6 minutes (Fig. 5E, stage iii). Collectively these results show
that in the present IL-1b-driven acute inflammation ICAM-2
facilitates neutrophil crawling to EC junctions and the initiation
of TEM but has no impact on the route or dynamics with which
neutrophils breach EC junctions.
The location of the observed periods of immobility during
discontinuous crawling in relation to EC junctions was analysed,
and compared to the location of a random selection of normally
crawling leukocytes in these vessels. The majority of these events
(79%) within ICAM-2 KO vessels were directly associated with
an endothelial junction, compared to only 56% of normally
crawling cells (Fig. 5F,G). In WT vessels, periods of immobility
were also predominantly associated with EC junctions, but were
much less frequently seen, and only eight periods of immobility
were observed in WT tissues. Coupled with the data showing that
there was a prolonged interaction with the junction prior to
initiating TEM (Fig. 5E, stage ii), these findings might indicate
that the periods of immobility during crawling represent
unsuccessful attempts to initiate junctional opening, suggesting
a possible role for ICAM-2 in the early stages of paracellular
TEM.
DISCUSSION
The current study employed a recently developed confocal
imaging system to investigate the role of ICAM-2 in the
dynamics of luminal neutrophil–venular-wall interactions in
vivo. The results revealed previously unreported roles for
luminal ICAM-2 in supporting efficient crawling through
ligation of neutrophil MAC-1. Furthermore, the current data
suggest that ICAM-2 might also be important in the initiation
or early stages of paracellular TEM. Collectively these roles
facilitate IL-1b-stimulated extravasation of neutrophils and might
thus be involved in supporting an efficient innate immune
response to infection and injury.
Unlike the expression of other EC adhesion molecules (e.g.
ICAM-1 and VCAM-1) that have been widely studied in vitro and
in vivo (Vestweber, 2007), the expression profile of ICAM-2 has
Fig. 5. IL-1b-stimulated TEM dynamics in ICAM-2 KO and WT mice. The
image sequences captured as described in Fig. 2 were also analysed for
the occurrence of TEM. (A) The frequency at which TEM was observed
following IL-1b stimulation was quantified in vessels from WT or ICAM-22/2/
LysM-EGFP+/2 mice over 30 minutes (the standard period of observation).
(B) The route of TEM (paracellular or transcellular) was quantified as
mean per venule. n560–196 cells from six to eight animals per group.
(C) Crawling behaviour that preceded TEM (continuous or discontinuous)
was quantified as mean per venule. n514–34 cells from six or seven
animals per group. (D) The sequence of events from crawling through to
completion of TEM was divided into three stages as illustrated. (i) Crawling:
the period for which a neutrophil crawls within the lumen prior to reaching
the site of TEM. (ii) Pre-TEM: the period for which a neutrophil interacts
with the endothelial junction at the location of TEM prior to any visible
disruption of the junctional integrity. (iii) TEM: the period from the first
visible disruption of junctional PECAM-1 to the completion of migration to the
sub-endothelial space. (E) The duration of stages i–iii as outlined in D was
quantified. n514–34 cells (stage i), 23–76 cells (stage ii), or 20–99 cells
(stage iii), from six or seven animals per group. (F) Periods of immobility
were observed during luminal crawling (Fig. 2E), and the location of these
events was analysed in relation to the location of EC junctions, and
compared to the location of a random selection of normally crawling cells
from the same vessels. n58 for WT and 77 for ICAM-2 KO immobile cells,
and 250 randomly selected crawling cells from six or seven animals per
group. (G) Examples of cells that were classified as being directly associated
with EC junctions, and others that were only partially in contact with a
junction, and not considered to be junction associated. Scale bars: 5 mm.
Results are mean6s.e.m. **P,0.01, ***P,0.001 between WT and ICAM-2
KO (Student’s t-test).
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not been extensively analysed. To address this issue, we extended
our previous work reporting on the heterogeneous distribution of
ICAM-2 on the non-junctional surface of cremaster venular ECs
(Woodfin et al., 2009) to a detailed quantitative analysis of EC
junctional and non-junctional expression of ICAM-2 as compared
to the EC junctional protein PECAM-1. In the mouse cremaster
muscle ICAM-2 was detected at non-junctional and junctional
regions of ECs to a comparable level, in contrast to PECAM-1
expression, which was largely detected at EC junctions. This
expression profile was also seen in mouse ear dermal venules,
suggesting that functional implications obtained from studies
within the cremaster might be broadly applicable to other tissues.
ICAM-2 has generally been considered to be a constitutively
expressed EC junctional protein (de Fougerolles et al., 1991;
Vestweber, 2007), and no regulation of the intensity or
distribution of either of these proteins was seen following IL-
1b stimulation. However, the constitutive luminal expression of
ICAM-2 reported in the present study opens up novel functional
possibilities. A limited number of studies have reported altered
expression of ICAM-2, although these include upregulation in
clinical scenarios of a more chronic and complex nature, such as
lymphoid malignancies (Renkonen et al., 1992) or Crohn’s
disease (Bernstein et al., 1998), or downregulation through
inhibition of transcription following prolonged exposure to
cytokines in HUVECs (McLaughlin et al., 1998). Of note, both
ICAM-2 KOs and WT mice upregulated ICAM-1 expression
following IL-1b stimulation, and no differences in the
upregulation or distribution of ICAM-1 was seen in these
animals.
Previous work from our group using fixed tissues has identified
sequential and non-redundant roles for ICAM-2, JAM-A
and PECAM-1 during paracellular neutrophil transmigration
(Woodfin et al., 2009), with a role for ICAM-2 being identified
in the earliest stages of TEM. In the light of the current findings
showing high luminal expression of ICAM-2, we hypothesised
that ICAM-2 might play a role in regulating luminal leukocyte–
endothelial interactions, in addition to a possible role during TEM
itself. This was investigated through the application of a high-
resolution confocal IVM system (Proebstl et al., 2012; Woodfin
et al., 2011) to analysis of leukocyte–EC interactions within
cremasteric venules of WT or ICAM-2-deficient LysM-EGFP-ki
mice, which have GFP-positive neutrophils. These studies
showed that in WT animals most luminally adherent
neutrophils exhibited some crawling motility and that overall
this was not dramatically altered in ICAM-2 KO mice. Similar
results were obtained in WT mice treated with a blocking anti-
ICAM-2 mAb, findings that are largely in agreement with
previously published work (Phillipson et al., 2006). However, in
ICAM-2 KO mice or mice treated with anti-ICAM-2 mAb the
mean crawling velocity of neutrophils was significantly slower
and there was greater variability in the speed of individual
crawling tracks. An increase in the observed duration of crawling
was also noted, indicating prolonged luminal interactions prior to
either TEM, or disengagement from the endothelium and return to
the circulation. Furthermore, in the absence of functional ICAM-
2, crawling neutrophils frequently exhibited a discontinuous
crawling behaviour characterised by prolonged periods of
immobility. So although ICAM-2 is not essential for luminal
crawling to occur, possibly because ICAM-1 has some
contribution to this response (Phillipson et al., 2006), our data
demonstrate for the first time a role for ICAM-2 in mediating the
speed and continuity of neutrophil luminal motility.
In addition to EC expression, neutrophils also express ICAM-2
and the potential role of the latter in the observed findings cannot
be ruled out. Indeed neutrophilic expression of ICAM-2 has
recently been linked to stabilisation of neutrophil rolling (Sundd
et al., 2012). However, through the use of passive transfer
experiments, we have previously obtained evidence for the
involvement of EC ICAM-2 and not leukocyte ICAM-2 in
leukocyte extravasation (Woodfin et al., 2009), strongly
suggesting a non-redundant role for EC ICAM-2 in leukocyte–
EC interactions.
To investigate the mechanism through which ICAM-2 mediates
neutrophil crawling dynamics in vivo, the role of the leukocyte
integrin MAC-1, a known binding partner for ICAM-2 (Xie et al.,
1995), was investigated. Of relevance, MAC-1 has previously been
implicated in leukocyte motility and crawling (Phillipson et al.,
2006; Sumagin et al., 2010). In line with previous findings (Huang
et al., 2006; Woodfin et al., 2009), normal levels of luminal
neutrophil adhesion, but reduced neutrophil extravasation, were
seen in ICAM-2-deficient conditions. In contrast, anti-MAC-1
mAb treatment partially reduced adhesion in both WT and ICAM-
2 KO mice, and substantially inhibited extravasation in WT
animals. The contribution of ICAM-1, which has overlapping
ligand specificities with ICAM-2 (Ding et al., 1999; Li et al., 1993;
Staunton et al., 1989; Xie et al., 1995), was also investigated.
Although ICAM-2 blockade or genetic deletion had no effect on
adhesion, ICAM-1 blockade had a profound inhibitory effect on
neutrophil adhesion as a result of which neutrophil extravasation
was almost totally abolished.
In addition to this ICAM-2 independent effect on adhesion,
MAC-1 inhibition also led to a reduced mean crawling velocity of
the remaining neutrophils and an increased frequency of
disrupted crawling events. These findings show a similar profile
of luminal leukocyte dynamics to those noted in ICAM-2 KO
mice, and dual inhibition of both MAC-1 and ICAM-2 had no
cumulative effects on luminal dynamics, suggesting that
interaction of these molecules might support efficient neutrophil
crawling in the present in vivo model.
In order to more directly investigate the role of MAC-1 in
ICAM-2 mediated crawling we employed a model in which the
functional roles of ICAM-2 or ICAM-1 in neutrophil crawling
could be examined in isolation. These results confirmed that
MAC-1 blockade inhibits crawling on ICAM-2 in the absence of
other MAC-1 ligands, supporting the assertion that ICAM-2–
MAC-1 ligation, as opposed to sequential functions within a
pathway, can support neutrophil crawling. In this simple in vitro
model, crawling on ICAM-1 is also inhibited by anti-MAC-1
mAb, and the functions of ICAM-1 and ICAM-2 appear to be
redundant. However the in vivo data presented in this and other
studies demonstrates that ICAM-1 cannot fully compensate for a
lack of ICAM-2 within post-capillary venules. The similarity in
crawling behaviour on ICAM-1 or ICAM-2 in vitro might
indicate that the different roles for these proteins observed in vivo
are not only dependent on the leukocyte locomotive machinery.
Whether the functional differences in vivo are due to differences
in EC expression levels, the binding specificity or the affinity of
these endothelial adhesion molecules to different integrins
(Casasnovas et al., 1997; Li et al., 1993; Li et al., 1995;
Staunton et al., 1989; Xie et al., 1995), the potential unique roles
for ICAM-2 in the opening of or entry to EC junctions, or a
combination of these possibilities, is not known at this time.
Collectively these findings, along with previously published
studies (Phillipson et al., 2006; Smith et al., 1989; Sumagin et al.,
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2010), suggest that both ICAM-1–LFA-1 and ICAM-1–MAC-1
pathways support initial neutrophil adhesion, whereas ICAM-2–
MAC-1 interaction supports efficient luminal crawling post-
adhesion, possibly through selective activation at the leading edge
of crawling neutrophils (Hidalgo et al., 2009).
In addition to a role in neutrophil luminal crawling dynamics,
we also investigated how TEM frequency and dynamics were
affected by the absence of ICAM-2. Whereas ICAM-2 KO mice
supported comparable numbers of adherent and crawling
neutrophils, very few cells exhibited a successful TEM
response. Of note, the TEM responses that did occur in both
WT and KO mice were primarily through the paracellular route,
in line with our previous findings (Woodfin et al., 2011). In the
light of the above findings showing a role for ICAM-2 in efficient
neutrophil crawling, we hypothesised that disrupted crawling
dynamics in ICAM-2 KO mice might account for reduced
neutrophil TEM events. In support of this, detailed analysis of
crawling behaviour of cells prior to successful TEM in the
ICAM-2 KO mice indicated a greater frequency of ‘continuous
crawling’ than is seen among the total crawling cell population.
These observations suggest that slower, discontinuous and
prolonged crawling hinders neutrophils in initiating a TEM
response. In addition, the duration of neutrophil contact with EC
junctions at sites of TEM prior to any observable disruption of the
junction was extended. However, although collectively we
observed delays in migration to, and opening of, EC junctional
pores, once TEM had commenced, the timeframe of breaching of
EC junctions was similar in both WT and ICAM-2 KO mice.
These findings are in line with our previous ex vivo studies that
showed that neutrophils arrest at an early stage of TEM in ICAM-2
KO mice (Woodfin et al., 2009), but significantly extend these
findings in terms of the observation of the neutrophil behaviour
prior to TEM, that is, the frequency at which these junction-
associated neutrophils progress to TEM, remain stationary or move
away from the junction. In addition, we have been able to
demonstrate that TEM progresses normally once initiated, without
further defects or delays in traversing the EC junction. This striking
absence of any role for ICAM-2 in the migration dynamics once
the neutrophil has entered the paracellular junction suggests that
the independent and sequential functions of other EC junctional
proteins in TEM come into play during the later stages of migration
through the junction (Bixel et al., 2010; Schenkel et al., 2002;
Sullivan et al., 2013; Woodfin et al., 2009; Woodfin et al., 2011).
The location of periods of immobility, which were frequently
exhibited by crawling neutrophils in the ICAM-2 KO mice, were
strongly associated with the EC junctions, and this observation
could provide a link between the defects in crawling continuity,
prolonged duration of pre-TEM junctional interactions, and the
overall reduced frequency of TEM. Putting these results together
a possible model to explain our findings is that in the absence of
EC ICAM-2 the greater frequency of transiently immobile
neutrophils represents cells that are attempting to enter the EC
junctions, and when unable to do so they resume crawling.
The prolonged interactions with EC junctions observed prior to
TEM (pre-TEM) described above, and the periods of immobility
associated with EC junctions which do not progress to TEM both
seem to involve neutrophil MAC-1, but whether the observed
dynamics arise from a defective mechanism within the neutrophils
or the endothelium is unknown. The lack of ICAM-2 ligation might
reduce the ability of neutrophils to form protrusions into the EC
junction, or simply that less-efficiently crawling neutrophils become
stuck at EC junctions that are not permissive for TEM, rather than
continuing to crawl efficiently until a more suitable site for TEM is
identified. Alternatively, ICAM-2 ligation at EC junctional contacts
might trigger signalling events within ECs through cytoskeletal
proteins such as a-actinin and ezrin-radixin-moesin proteins, which
facilitate the opening of EC junctions and allow the junction-
associated neutrophils to begin TEM (Heiska et al., 1996; Heiska
et al., 1998; Helander et al., 1996; Yonemura et al., 1998).
In conclusion, the results presented here demonstrate a number of
novel roles for ICAM-2 in neutrophil–EC interactions that support
efficient extravasation, namely supporting efficient neutrophil
crawling dynamics and in the opening or identification of EC
junctions. It remains to be determined whether these responses are
inter-related or represent distinct roles for ICAM-2, but speculating
that crawling is supported by activation of leukocyte locomotive
machinery (e.g. through ligation of MAC-1), whereas EC junctional
opening is be facilitated by the formation of neutrophil protrusions
or signalling within ECs provides an attractive platform for future
investigations.
MATERIALS AND METHODS
Animals
Male wild-type (WT) C57BL/6 mice (20–25 g) were purchased from
Charles River Laboratories (Margate, UK). ICAM-2 KO mice (Gerwin
et al., 1999) were a gift from Britta Engelhardt (Theodor Kocher Institute,
University of Bern, Switzerland). The primary strain used for live
imaging were mice in which the gene for EGFP has been knocked-in to
the lysozyme M (LysM) locus (LysM-EGFP-ki) (Faust et al., 2000),
resulting in the expression of EGFP in myelomonocytic cells, with high
levels of EGFP in neutrophils and to a lesser extent monocytes. ICAM-
22/2/LysM-EGFP+/2 mice were generated in-house by interbreeding
ICAM-2 KO mice with LysM-EGFP-ki mice, yielding animals deficient
in ICAM-2 protein with GFP-positive neutrophils and monocytes. Only
mice heterozygotic for LysM-EGFP-ki were used in the study. All
genetically modified animals were on a C57BL6 background. All animals
were housed in individually ventilated cages, and facilities were regularly
monitored for health status and infections. All experiments were
performed under the UK legislation for the protection of animals, and
at the end of all in vivo procedures animals were humanely killed by
cervical dislocation in accordance with UK Home Office regulations.
Reagents
Recombinant mouse interleukin-1b (IL-1b), recombinant mouse ICAM-2
and recombinant mouse and human ICAM-1 were purchased from R&D
systems (Abingdon, UK). Tyrode’s salts was purchased from Sigma-
Aldrich (Poole, YK). R10 tissue culture medium was from Gibco (NY,
USA). Anti-ICAM-2 monoclonal antibody (mAb) (3C4; rat IgG2a) and
isotype control mAbs (rat IgG2a and rat IgG2b) were obtained from
Serotec (Kidlington, UK). Anti-ICAM-1 mAb (YN-1; rat IgG2b) and
anti-PECAM-1 mAb (C390; rat IgG2a) were from eBiosciences
(Hatfield, UK). Anti-MAC-1 mAb (M1/70; rat IgG2b), Alexa-Fluor-
488-labelled anti-ICAM-2 mAb (3C4; rat IgG2a) was purchased from
Biolegend (Cambridge, UK). Monoclonal antibody Alexa Fluor
conjugation kits and Calcein-AM were from Invitrogen (Paisley, UK),
and the anti-PECAM-1, anti-VE-cadherin and anti-ICAM-1 mAbs were
conjugated to either Alexa Fluor 488, 555 or 647 in-house.
Analysis of EC protein expression
Confocal microscopy was used to analyse endothelial expression of
PECAM-1, VE-cadherin, ICAM-2 and ICAM-1 in saline (control) or
IL-1b-stimulated cremaster muscles or ear dermis from WT and ICAM-2 KO
mice. Animals were sedated through intramuscular (i.m.) injection of 1 ml/
kg anaesthetic (40 mg per kg of body weight ketamine and 2 mg per kg of
body weight xylazine in saline), and intrascrotal (i.s.) injection of IL-1b
(50 ng/400 ml saline) or saline alone. Saline or IL-1b were co-administered
with non-blocking Alexa-Fluor-conjugated anti-PECAM-1 (2 mg), anti-
ICAM-1 (4 mg) or anti-ICAM-2 (4 mg) mAbs. For VE-cadherin labelling,
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tissues were fixed with 4% PFA, blocked and permeabilised, then incubated
with Alexa-Fluor-conjugated anti-VE-cadherin. For analysis of the mouse ear
dermis, anti-ICAM-2 mAb was given (i.v. 3 mg per kg of body weight) prior
to cervical dislocation, and ears were removed and fixed in 4% PFA. The
dermis was separated from the cartilage layer, blocked and permeablised,
incubated with a fluorescent secondary antibody to anti-ICAM-2 mAb
(1 mg), then with Alexa-Fluor-conjugated anti-PECAM-1 mAb (2 mg).
Tissues were viewed using a Leica SP5 confocal microscope
incorporating a 206water-dipping objective (NA 1.0). z-stack images of
three to five post-capillary venules per cremaster with 20–45 mm diameter
were selected for analysis (three or four mice per group). Image processing
and quantification of protein expression levels on venular ECs was carried
out using Imaris (Bitplane) 3D analysis software. A differential analysis of
the intensity of EC junctional and non-junctional expression levels was
carried out by creating isosurfaces (Proebstl et al., 2012) with intensity
threshold settings on either the high-intensity PECAM-1 at the EC
junctions, or on the low-intensity PECAM-1 on the EC bodies. The
intensity of PECAM-1, ICAM-1 and ICAM-2 within these regions could
then be determined in saline and IL-1b-stimulated cremaster muscles
(supplementary material Fig. S4). The linear intensity profile of protein
expression (Fig. 1B) was quantified from a maximal intensity projection of
the z-stack using the Leica LAS-AF software.
Luminal leukocyte–EC interactions in vivo
Luminal leukocyte–EC interactions were analysed using confocal IVM as
previously described (Proebstl et al., 2012; Woodfin et al., 2011). The
cremaster muscles of sedated WT or ICAM-22/2/LysM-EGFP+/2 mice
were stimulated with i.s. saline or IL-1b, co-administered with a non-
blocking Alexa-Fluor-555-labelled PECAM-1 antibody (2 mg) to visualize
the endothelium. For ICAM-2, ICAM-1, and MAC-1 blocking
experiments, the blocking or isotype control mAbs were administered
i.v. (3 mg per kg of body weight) 15 minutes before IL-1b stimulation.
Mice were prepared for confocal IVM 2 hours after i.s. injections in
order to observe firmly adherent leukocytes undergoing crawling and/or
TEM for a further 2 hours. Briefly, mice were anesthetized by
intraperitoneal (i.p.) injection of ketamine (100 mg per kg of body
weight) and xylazine (10 mg per kg of body weight) and maintained at
37 C˚ on a custom-built, heated microscope stage. The cremaster muscle
was exteriorized, pinned out flat over the optical window of the stage,
and superfused with warm Tyrode’s balanced salts solution.
Images were acquired by sequential scanning of the 488 and 561 nm
channels at a resolution of 10246350 pixels in the x,y plane and 1.0 mm
steps in the z plane, corresponding to a voxel size of 0.4160.4160.99 mm
in the x,y,z planes, respectively. Confocal images were acquired with a
Leica SP5 confocal microscope using a resonance scanner of 8000 Hz.
Acquisition of a single z-stack of ,60 images routinely took
,30 seconds. Images were captured every 30 seconds for a further
2 hours, for 30–40 minutes per vessel [see movies for examples of an
uninflamed vessel (supplementary material Movie 1) and an IL-1b-
stimulated inflamed vessel (supplementary material Movie 2)].
To confirm the effect of genetic or pharmacological interventions, still
images of three to five post-capillary venules per cremaster muscle were taken
at the end of the experiment (,4 hours after i.s. injections), and intravascular
and extravascular leukocytes were quantified for a 500-mm vessel length for
intravascular, and a 500-mm vessel length extending 50 mm into the
perivascular tissue for extravasated cells (2.56104 mm2).
Analysis of luminal leukocyte crawling dynamics
Post-acquisition sequential z-stacks were analysed using the software
Imaris, which renders the stacks of optical sections into sequential 3D
models, thereby enabling the dynamic interactions between luminal EC
and leukocytes to be observed, tracked and analysed. All images and
videos show half vessels to enable clear visualization of the luminal
surface of the vessel wall. Using this technique, luminal leukocyte
crawling and TEM profile and dynamics were quantified.
Specific parameters were established for investigating the profile and
dynamics of leukocyte luminal crawling on ECs. For each image
sequence, luminal cells that were clearly visible in terms of their location
and dynamics for five or more frames (.2.5 minutes), were manually
tracked and analysed. Approximately 70 crawling cells were analysed
from three to eight mice per group. Crawling leukocytes were defined as
any leukocyte which had a displacement more than approximately half a
cell radius (5 mm) over the period of observation (supplementary material
Movie 3). Non-crawling, or stationary, cells were defined as any
leukocyte which had a displacement less than half a cell radius (,5 mm)
over the period of observation (supplementary material Movie 4).
Individual luminal crawling paths were tracked manually using Imaris,
and the following parameters were quantified: duration of crawling
(minutes), speed of crawling (mm/minute), distance crawled (mm), total
displacement (straight line distance between the first and last track point),
crawling displacement direction relative to blood flow, crawling
straightness (ratio of crawling displacement length to crawling track
length) and crawling speed variation (standard deviation of the crawling
speed per cell, divided by the mean crawling speed per cell).
Two distinct types of leukocyte crawling behaviours were routinely
observed, ‘continuous crawling’ and ‘discontinuous crawling’, and the
frequency at which they occurred was quantified. Leukocytes were
classified as exhibiting continuous crawling if they were mobile for the
duration of observation. Supplementary material Movie 5 shows an example
of a continuously crawling cell. Discontinuous crawling was defined as
crawling behaviour with periods of immobility of 2.5 minutes or greater
during the period of observation. Immobility was defined by a cell
displacement of less than approximately half a cell radius (5 mm). See
supplementary material Movie 6 for an example of discontinuous crawling.
The location of each period of immobility exhibited by crawling cells was
quantified in relation to EC junctions. Neutrophils were determined to be
directly associated with EC junctions or as partially and not in contact with EC
junctions. Cells with partial contact with an EC junction were not deemed to
be junction associated, as the morphology of the ECs and their junctions mean
that any randomly placed neutrophil-sized object would often have some
degree of junctional contact, and this is not equivalent to the position cells are
seen in immediately prior to commencing TEM (see Fig. 4G for examples).
The location of periods of immobility were compared to the location of
randomly selected crawling cells from the same vessels, taken from the first
and last time point of each image sequence.
Analysis of leukocyte TEM dynamics
TEM events which were clearly visible for the duration of their migration
through the EC layer were analyzed. Paracellular and transcellular TEM
events were identified through the observation of leukocyte TEM through the
ECs, and the occurrence of transient pores in EC junctional or non-junctional
PECAM-1 staining during a TEM event (Woodfin et al., 2011). Luminal
events leading up to TEM were also analysed. This included the duration of
luminal crawling to the EC junction that would be the eventual site of TEM,
and the duration for which leukocytes were in contact with the EC junction
prior to commencing TEM (the point at which junctional disruption is
observed), which was termed ‘pre-TEM’.
It is important to note that both crawling and TEM analyses relate only to
the time for which each cell was observed during the limited 30–40-minute
observation period, and within the,200-mm-long vessel segment in the field
of view. In many cases, cells that were already adherent at the beginning of
observation, were still exhibiting luminal crawling at the end of the period of
observation, or simply crawled out of the field of view, and as such their
ultimate fate is unknown. It is only possible to observe the full sequence of
initial adhesion, crawling and TEM in a small subset of cases. The limitations
inherent here are, however, equal across all groups, so recorded differences in
behaviour between groups are valid in terms of relative difference.
In vitro crawling assay
Neutrophils were isolated from the blood of male C57BL/6 mice
using an anti-Ly6G MicroBead kit (Miltenyl Biosciences) as per the
manufacturer’s instructions. Neutrophil purity obtained using these kits is
.90% (not shown). The neutrophils were fluorescently labelled with
Calcein-AM (1 mg/ml, 30 minutes at 37 C˚), and 50,000 neutrophils per
chamber were seeded into culture slides (BD Flacon) and allowed to
adhere. Culture slides were uncoated, or coated with recombinant human
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ICAM-1 (2.5 mg/ml) or recombinant mouse ICAM-2-FC (10 mg/ml)
overnight, then blocked with 10% BSA for 2 hours. Isotype control or
anti-MAC-1 mAbs were added (10 mg/ml) following neutrophil adhesion
and removal of non-adherent cells. Adherent neutrophils were imaged at
2 min intervals for 40 minutes using an Olympus IX8 inverted
microscope with a 106 objective lens, while being maintained at 37 C˚
and 10% CO2. Crawling dynamics were quantified using Imaris, and any
remaining non-adherent cells were excluded from analysis.
Statistics
Results are presented as mean6s.e.m. Statistical significance was
assessed by Student’s t-test or one-way analysis of variance (ANOVA)
with the Newman-Keuls multiple comparison test. P-values below 0.05
were considered significant.
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